# Ainos, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Ainos, Inc.).

## Overview

Ainos, Inc. is a Texas-based healthcare and technology company that combines drug development with scent-digitalization and AI sensing. Its core programs center on VELDONA, an oral low-dose interferon platform being developed for human and animal health, and AI Nose, a VOC-sensing technology intended to convert odors into digital Smell IDs. The company also has commercialized or previously commercialized products such as VELDONA Pet and a COVID-19 antigen rapid test kit, while it continues to advance new diagnostics and therapeutics through partnerships. Ainos is still in a development-heavy stage, with commercialization, licensing, and strategic collaborations used as the main path to build revenue streams.

## Products & services

• VELDONA Pet animal health supplement
• VELDONA human drug candidates
• AI Nose VOC sensing / Smell ID platform
• VOC POCT and Ainos Flora diagnostics
• COVID-19 antigen rapid test kit
• Synthetic RNA (SRNA) platform
• Strategic co-development and out-licensing

- **Therapeutics** (0%) — VELDONA oral low-dose interferon programs for human diseases and animal health.
- **Diagnostics** (35%) — Point-of-care and rapid test products, including VOC-based and antigen testing.
- **Animal Health** (20%) — VELDONA Pet products sold for dogs and cats in Taiwan.
- **AI Sensing Platform** (40%) — AI Nose and VOC sensing technologies for digitizing scent into usable data.
- **Licensing and Partnerships** (5%) — Co-development, commercialization partnerships, and out-licensing of IP and pipeline assets.

- VELDONA Pet animal health supplement
- VELDONA human drug candidates
- AI Nose VOC sensing / Smell ID platform
- VOC POCT and Ainos Flora diagnostics
- COVID-19 antigen rapid test kit
- Synthetic RNA (SRNA) platform
- Strategic co-development and out-licensing

## Customers

Ainos sells to a mix of end users, channel partners, and development collaborators rather than relying on a single large customer base. In the near term, revenue has come from product sales of VELDONA Pet in Taiwan and from VOC sensing products tied to the NISD co-development arrangement. The company’s future customer base is broader and more application-specific, including healthcare providers, patients, pet owners, robotics developers, industrial users, and environmental safety applications. Because many of its programs are still in development, strategic partners and licensees are also important customers in practice, since they help fund commercialization and validate the technology. This makes Ainos more of a platform-and-pipeline company than a traditional commercial pharmaceutical seller.

- **Pet owners and veterinary channel** (primary) — Buy VELDONA Pet in Taiwan for companion-animal wellness uses such as skin, gum, allergy, eye, and weight-related issues.
- **Strategic co-development partners** (primary) — Purchase or help commercialize VOC sensing products and modules through the NISD and Taiwan Inabata collaboration.
- **Healthcare and diagnostics users** (secondary) — Target users for AI Nose, VOC POCT, and Ainos Flora products that aim to support telehealth and point-of-care testing.
- **Pharmaceutical and clinical end markets** (secondary) — Potential patients and providers for VELDONA human programs in oral warts, Sjögren’s syndrome, influenza, and mild COVID-19.
- **Industrial and robotics customers** (emerging) — Users of scent-digitization and VOC sensing for robotics, smart manufacturing, and environmental safety applications.

- Pet owners in Taiwan buying VELDONA Pet for dogs and cats
- Co-development partners purchasing VOC sensing products and modules
- Healthcare users targeted for AI Nose diagnostics and POCT applications
- Patients and physicians targeted by VELDONA human drug programs
- Robotics and industrial customers seeking scent-detection capabilities
- Environmental safety users needing VOC monitoring applications
- Licensees and strategic partners that commercialize Ainos IP

## Geography

Ainos is incorporated in Texas and reports as a U.S.-based company, but its commercial activity is heavily tied to Asia. The company currently sells VELDONA Pet in Taiwan and has also generated revenue from VOC sensing products related to a co-development arrangement. Its strategic partnerships include Japanese and Taiwanese counterparties, which makes Asia central to both commercialization and product development. The company also references U.S. regulatory milestones, including FDA orphan drug designation for one VELDONA program, so its pipeline has both U.S. and Asia-facing elements. Geography matters because the business depends on cross-border sourcing, partner execution, and foreign exchange exposure.

- Headquartered in Texas, United States
- Commercial sales of VELDONA Pet in Taiwan
- VOC sensing revenue tied to Taiwan/Japan co-development activity
- Strategic partnership with a Japanese robot developer
- Taiwan and Japan are important for commercialization and R&D
- U.S. regulatory pathway remains relevant for human drug programs
- Foreign exchange and trade policy can affect cross-border operations

## Strategy

Ainos is trying to build multiple revenue streams by combining product sales, out-licensing, and strategic partnerships around a common IP base. Near-term priorities include advancing AI Nose partnerships, progressing the lead POCT candidate Ainos Flora, and continuing clinical studies for VELDONA programs. The company also expects to increase R&D spending as it pushes VOC POCT and VELDONA through development, while selectively expanding sales and marketing. Because internal cash is limited, financing strategy remains part of the operating plan, with convertible notes, equity issuance, and other external funding used to support execution. The strategic challenge is to convert a broad technology portfolio into repeatable commercial demand before capital resources are exhausted.

- **Commercialize AI Nose through partnerships** (short-term) — Partnerships are the fastest route to market for a sensing platform that needs application-specific adoption in robotics, telehealth, and industrial settings.
- **Advance VOC POCT and Ainos Flora** (short-term) — These products are intended to create nearer-term diagnostic revenue and validate the company’s healthcare platform.
- **Progress VELDONA clinical and licensing strategy** (medium-term) — Clinical data and orphan-drug positioning can support future licensing, partnering, or commercialization in human therapeutics.
- **Preserve liquidity through external financing** (short-term) — The company needs ongoing capital to fund R&D, clinical work, and commercialization before product revenues become self-sustaining.

- Advance AI Nose partnerships to turn sensing IP into commercial use cases
- Develop VOC POCT and Ainos Flora as nearer-term diagnostic products
- Continue clinical studies for VELDONA human programs
- Out-license pipeline assets to monetize IP without full internal commercialization
- Use strategic partnerships to reduce commercialization burden
- Increase R&D investment to support product and clinical milestones
- Maintain access to external financing to fund operations

## Risks

Ainos faces the classic risks of a development-stage biotech and diagnostics company: clinical failure, regulatory delay, and uncertain commercialization timing. Its business model depends on converting early-stage technologies into partner-backed products, so execution risk is high if collaborations do not scale or if end-market adoption is slower than expected. The company also has meaningful financing risk because it expects to rely on cash, revenues, and external funding to support operations over the next twelve months. Reported risks specifically include foreign exchange volatility and trade-policy changes, which matter because the company operates across the U.S., Taiwan, Japan, and other jurisdictions. More broadly, competition in diagnostics, animal health, and digital sensing could pressure pricing and reduce the value of its IP if larger players move faster.

- **Clinical trial and development failure** [high] — VELDONA, VOC POCT, and SRNA are still being developed, so unfavorable data or delays could prevent commercialization.
- **Liquidity and financing dependence** [critical] — The company states it will need additional capital and may exhaust available resources sooner than expected.
- **Foreign exchange volatility** [medium] — Cross-border operations and sales in Asia expose results to currency movements.
- **Trade policy and tariff disruption** [medium] — Tariffs, import/export restrictions, and retaliatory trade actions could raise component costs or reduce demand.
- **Commercial adoption risk** [high] — AI Nose and VOC sensing require partner and customer adoption in new use cases, which may take time to prove.

- Clinical development risk for VELDONA and VOC POCT candidates
- Regulatory risk from FDA and other health authority approvals
- Financing risk due to dependence on external capital
- Foreign exchange volatility affecting cross-border costs and revenue
- Trade policy and tariff changes disrupting sourcing and sales
- Partner execution risk in co-development and commercialization
- Adoption risk for new AI Nose and scent-digitization applications

## Accounting

Ainos’ reported results are highly sensitive to judgmental accounting because the company is still early in commercialization and relies heavily on non-cash financing and stock-based compensation. Revenue is small and can fluctuate sharply quarter to quarter because product sales and co-development revenue depend on discrete transactions, making period comparisons noisy. The company also highlights estimates around inventory valuation, useful lives of property and equipment, valuation of stock options, warrants and convertible notes, and impairment testing of intangible assets, all of which can materially affect reported earnings and balance sheet values. Share-based compensation and depreciation/amortization are significant relative to revenue, so investors should watch how non-cash costs distort operating trends. Convertible note accounting and fair value measurement are especially important because financing instruments can create interest expense, issuance costs, and valuation changes that move net loss without reflecting core operating performance.

- **Revenue timing and transaction mix** — Makes trend analysis difficult and can distort growth rates
- **Stock-based compensation** — Affects operating loss and comparability across periods
- **Convertible notes and fair value estimates** — Impacts financing costs, liabilities, and earnings
- **Impairment testing of intangible assets** — Could lead to non-cash write-downs

- Revenue can be lumpy because it depends on product sales and co-development transactions
- Stock-based compensation materially affects SG&A and R&D expense
- Convertible note accounting affects interest expense and issuance costs
- Fair value estimates for warrants and notes can change reported results
- Inventory valuation matters for small product batches and changing product mix
- Intangible asset impairment risk is relevant for early-stage IP and pipeline assets
- Depreciation and amortization can be significant relative to low revenue

---

*Last updated: 2026-08-11T04:46:19.742292+00:00*